Anti Hypertensive Prescribing Patterns and Cost Analysis for Primary Hypertension: A Retrospective Study

Pr, Rachana; Hv, Anuradha; Shivamurthy, M.

doi:10.7860/jcdr/2014/9567.4890

Cited by 18 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An estimate by the World Health Organization (WHO) revealed that around 9.4 million deaths occur per year because of hypertension. The majority of study participants in the present study were males i.e.56.66% and female patients were i.e.43.33%, similar results were found in another study (PR, 2014;Xavier, Mathew, Pradeep, & Pais, 2001). However, some studies have reported a relatively higher incidence of hypertension in females than in males (Beg et al, 2014;Tiwari, Kumar, & Kulkarni, 2004).…”

Section: Discussionsupporting

confidence: 91%

comparative study on efficacy of chlorthalidone and azilsartan in confirmed cases of hypertension associated with ace gene polymorphism

Chaithanya¹,

Gorantla²,

Addepalli³

et al. 2022

ijhs

View full text Add to dashboard Cite

The angiotensin-converting enzyme (ACE) gene consists of 26 exons, it is located on chromosome 17 and its polymorphism is a major contributing factor to hypertension. The aim is to compare the efficacy of Chlorthalidone and Azilsartan in newly diagnosed hypertension patients in association with ACE gene polymorphism. The study was conducted in the department of pharmacology, Rama medical college, Kanpur. After doing genetic test and basic investigation, 90 newly diagnosed patients with hypertension associated with ACE gene polymorphism were recruited, followed by grouping into two A&B. Group-A(n=45) patients were given Azilsartan 45mg/day and group-B(n=45) patients were given Chlorthalidone 25mg/day for 3 months. Systolic and diastolic blood pressure (SBP& DBP) was measured before and after 3 months of treatment in both groups and they were compared. Three genotypes were found in ACE gene polymorphism-associated hypertension cases such as I/I, I/D and D/D, the severity of hypertension is more in the D/D genotype followed by I/D and I/I genotypes. All three genotypes of both group-A & B had shown a significant mean reduction in SBP& DBP after 3 months of treatment (p<0.05) but the mean reduction was high in the I/I genotype followed by the I/D and then D/D genotype.

show abstract

Section: Discussionsupporting

confidence: 91%

comparative study on efficacy of chlorthalidone and azilsartan in confirmed cases of hypertension associated with ace gene polymorphism

Chaithanya¹,

Gorantla²,

Addepalli³

et al. 2022

ijhs

View full text Add to dashboard Cite

show abstract

“…Some prescription pattern studies also support this finding where CCBs were prescribed more compared to the other types of antihypertensive drugs. [1617] A number of factors guide the choice of antihypertensive treatment including comorbidities, concomitant medications, physician's preference as per the patient characteristics, guidelines followed by the hospital, as well as the availability of medicines.…”

Section: Discussionmentioning

confidence: 99%

“…This prescription pattern of amlodipine has also been observed in other drug utilization studies. [1617] Amlodipine has acceptable safety and efficacy, also strong evidence from many randomized controlled trials for cardiovascular event reduction. [23]…”

Section: Discussionmentioning

confidence: 99%

Prescription pattern of antihypertensive drugs: An experience from a secondary care hospital in the United Arab Emirates

et al. 2019

View full text Add to dashboard Cite

Objective: The aim of the study was to examine the prescription pattern of antihypertensive drugs used in a secondary care hospital in the United Arab Emirates (UAE). Methods: It was a prospective, observational study carried out in 588 adult hypertensive patients presenting to medicine outpatient and inpatient departments of Dibba Hospital, Fujairah, UAE. The study was conducted for a period of 6 months from December 2017 to May 2018. Demographic and clinical data were collected from electronic patient case records and documented. Prescriptions were studied overall for drug use details and for specific types of antihypertensive drugs. The World Health Organization Anatomical Therapeutic Chemical/Defined Daily Dose methodology was further used to calculate utilization. Statistical analysis of data was performed using Statistical Package for the Social Sciences 24.0. Findings: Of the 588 study participants, majority of the patients were on two-drug combination antihypertensive therapy ( n = 210, 35.5%) followed by monotherapy ( n = 188, 32.1%) and three-drug combination ( n = 136, 23.1%). Calcium channel blockers were the most frequently (51%) prescribed class both in monotherapy and in combination therapy while angiotensin receptor blockers and angiotensin-converting enzyme inhibitors (55.9%) were the most preferred agents for monotherapy. Among individual antihypertensive drugs, amlodipine was prescribed the most (266 prescriptions), irrespective of monotherapy or combination therapy. Conclusion: Our study represents the current prescribing trends of antihypertensive drugs in a secondary care hospital in the UAE. The use of antihypertensive drugs largely conforms to international guidelines, but still, there is room for improvement in terms of rational drug utilization.

show abstract

“…Terapi obat antihipertensi yang tepat adalah penting karena prevalensi hipertensi telah meningkat dalam tiga dekade terakhir. Setiap penyimpangan pedoman pengobatan hipertensi berkontribusi pada tingginya biaya pengobatan dan kesulitan dalam menyediakan resep yang terjangkau 21 .…”

Section: 314unclassified

Cost Effectiveness Kombinasi Antihipertensi Candesartan-Bisoprolol dan Candesartan-Amlodipin Pada Pasien Rawat Jalan Penderita Hipertensi

Nurhikma¹,

Wulaisfan²,

Musdalipah³

2019

JPM

View full text Add to dashboard Cite

Today, in various countries, especially in Indonesia, the cost of health services is increasing. Hypertension is a degenerative disease that requires health costs for a long time. Increasing costs due to increasing chronic diseases threaten access and quality of health services, by which it is necessary to find a solution to overcome the problem of health financing. One method used is to analyze the guidelines for hypertension therapy and drug classes in the pharmacoeconomic aspects, namely Cost Effectiveness Analysis. This study aims to analyze the effectiveness of antihypertensive combination therapy in hypertensive patients at Bhayangkara Hospital, Kendari in 2019. The research method is descriptive with cross sectional study design. The analysis conducted is the cost effectiveness analysis (CEA) performed by calculating direct medical costs, the effectiveness of therapy based on blood pressure that reaches the target and calculating the value of ACER (Average Cost Effectiveness Ratio) and ICER (Incremenal Cost Effectiveness Ratio). Data were collected prospectively which fulfilled the inclusion and exclusion criteria. The results showed the therapeutic effectiveness and the value of ACER obtained from 31 hypertensive patients were a combination of Candesartan – Bisoprolol that was ACER value of 85.71% (2,314), and combination of Candesartan – Amlodipin of 70.58% (2,643). ICER value of 7,832 indicates that the price of drugs is more expensive but more effective therapy.Keywords : cost effective, ACER, ICER, Hypertension, Candesartan, Amlodipin Abstrak: Dewasa ini, diberbagai negara khususnya di Indonesia biaya pelayanan kesehatan semakin meningkat. Hipertensi merupakan salah satu penyakit degeneratif yang membutuhkan biaya kesehatan dalam jangka waktu yang lama. Peningkatan biaya akibat semakin meningkatnya penyakit kronik mengancam akses dan mutu pelayanan kesehatan, olehnya itu perlu dicari solusi untuk mengatasi masalah pembiayaan kesehatan. Salah satu metode yang dilakukan yaitu dengan menganalisis pedoman terapi hipertensi dan golongan obat dalam aspek farmakoekonomi, yaitu Analisis Efektivitas Biaya. Penelitian ini bertujuan untuk menganalisis efektivitas terapi kombinasi antihipertensi pada pasien hipertensi di Rumah Sakit Bhayangkara Kendari tahun 2019. Metode penelitian ialah deskriptif dengan rancangan cross sectional study. Data diambil secara prospektif yang memenuhi kriteria inklusi dan eksklusi. Analisis yang dilakukan adalah cost effectiveness analysis (CEA) dilakukan dengan menghitung biaya medik langsung, efektivitas terapi berdasarkan tekanan darah yang mencapai target dan menghitung nilai ACER (Average Cost Effectiveness Ratio) dan ICER (Incremenal Cost Effectiveness Ratio). Hasil penelitian menunjukkan efektifitas terapi dan nilai ACER yang diperoleh dari 31 pasien hipertensi ialah kombinasi Candesartan – Bisoprolol yaitu nilai ACER sebesar 85,71% (2.314), dan kombinasi Candesartan – Amlodipin sebesar 70,58% (2.643). Nilai ICER sebesar 7.832 menunjukkan bahwa harga obat lebih mahal namun terapi lebih efektif. Kata Kunci : Efektivitas biaya, ACER, ICER, Hipertensi, Candesartan, Amlodipin

show abstract

Anti Hypertensive Prescribing Patterns and Cost Analysis for Primary Hypertension: A Retrospective Study

Cited by 18 publications

References 22 publications

comparative study on efficacy of chlorthalidone and azilsartan in confirmed cases of hypertension associated with ace gene polymorphism

comparative study on efficacy of chlorthalidone and azilsartan in confirmed cases of hypertension associated with ace gene polymorphism

Prescription pattern of antihypertensive drugs: An experience from a secondary care hospital in the United Arab Emirates

Cost Effectiveness Kombinasi Antihipertensi Candesartan-Bisoprolol dan Candesartan-Amlodipin Pada Pasien Rawat Jalan Penderita Hipertensi

Contact Info

Product

Resources

About